Nicole Lapinel, MD
Pulmonary Disease · New Orleans, LANPI 1376860494
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $100,647 of the $140,407 with a category attached, or 71.7%. Insmed, Inc. accounts for 99.7% of it on its own, with 5 other manufacturers making up the rest. Among pulmonary disease clinicians in LA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 141 payments — averaging $995.80 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Insmed, Inc.$140K
- Alcresta Therapeutics, Inc.$150
- Mylan Specialty L.p.$107
- Boehringer Ingelheim$69
- Actelion Pharmaceuticals US, Inc.$43
- AstraZeneca$18
Across 20 payments — averaging $4234.62 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Paratek Pharmaceuticals, Inc.$85K
What the payments were for
- Consulting fees$100,64772%
- Speaking & faculty fees$12,2009%
- Travel & lodging$24,04117%
- Food & beverage$3,4202%
- Education$1000%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Insmed, Inc. | 135 | $140,020 |
| Alcresta Therapeutics, Inc. | 1 | $150 |
| Mylan Specialty L.p. | 1 | $107 |
| Boehringer Ingelheim | 1 | $69 |
| Actelion Pharmaceuticals US, Inc. | 2 | $43 |
| AstraZeneca | 1 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Arikayce$95,692
- RELIZORB$150
- TOBI Podhaler$107
How this compares
$140,407 in reported general payments places this provider in the 95th percentile of 189 pulmonary disease providers in Louisiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 16 | $10,213 |
| Ethambutol Hcl | 47 | $1,516 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 33 | $865 |
| Azithromycin | 53 | $742 |
| Rifampin | 21 | $541 |
| Fluticasone Propionate | 24 | $383 |
| Famotidine | 59 | $156 |
Paid to pharmacies, not to this prescriber.
Other pulmonary disease in New Orleans
- Joseph LaskyNew Orleans$447K
- Ramsy AbdelghaniNew Orleans$308K
- Juzar AliNew Orleans$216K
- Courtney ShappleyNew Orleans$66K
- Susan GunnNew Orleans$28K
- David PattenNew Orleans$12K
- Yasin KhanNew Orleans$12K
- Ross KlingsbergNew Orleans$11K
- Nereida ParadaNew Orleans$10K
- Leonard GladeNew Orleans$10K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.